- Home
- CMMB vs NXGL Comparison
CMMB vs NXGL Comparison
Compare CMMB & NXGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- NXGL
- Stock Information
- Founded
- CMMB 2004
- NXGL 1997
- Country
- CMMB Israel
- NXGL United States
- Employees
- CMMB N/A
- NXGL N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- NXGL Medical/Dental Instruments
- Sector
- CMMB Health Care
- NXGL Health Care
- Exchange
- CMMB Nasdaq
- NXGL Nasdaq
- Market Cap
- CMMB 13.8M
- NXGL 15.6M
- IPO Year
- CMMB N/A
- NXGL 2021
- Fundamental
- Price
- CMMB $2.54
- NXGL $1.82
- Analyst Decision
- CMMB Strong Buy
- NXGL
- Analyst Count
- CMMB 2
- NXGL 0
- Target Price
- CMMB $26.50
- NXGL N/A
- AVG Volume (30 Days)
- CMMB 80.5K
- NXGL 86.1K
- Earning Date
- CMMB 11-20-2025
- NXGL 11-11-2025
- Dividend Yield
- CMMB N/A
- NXGL N/A
- EPS Growth
- CMMB N/A
- NXGL N/A
- EPS
- CMMB N/A
- NXGL N/A
- Revenue
- CMMB N/A
- NXGL $11,666,000.00
- Revenue This Year
- CMMB N/A
- NXGL $46.60
- Revenue Next Year
- CMMB N/A
- NXGL $47.96
- P/E Ratio
- CMMB N/A
- NXGL N/A
- Revenue Growth
- CMMB N/A
- NXGL 73.37
- 52 Week Low
- CMMB $2.36
- NXGL $1.56
- 52 Week High
- CMMB $9.84
- NXGL $5.10
- Technical
- Relative Strength Index (RSI)
- CMMB 42.45
- NXGL 39.70
- Support Level
- CMMB $2.36
- NXGL $1.68
- Resistance Level
- CMMB $2.85
- NXGL $2.56
- Average True Range (ATR)
- CMMB 0.20
- NXGL 0.17
- MACD
- CMMB -0.02
- NXGL -0.02
- Stochastic Oscillator
- CMMB 32.71
- NXGL 29.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.